Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction.
HIV-1 entry into host cells is mediated by the sequential binding of the envelope glycoprotein gp120 to CD4 and a chemokine receptor. Antibodies binding to epitopes overlapping the CD4-binding site on gp120 are potent inhibitors of HIV entry, such as the llama heavy chain antibody fragment V(HH) D7, which has cross-clade neutralizing properties and competes with CD4 and mAb b12 for high affinity binding to gp120. We report the crystal structure of the D7 V(HH) at 1.5 A resolution, which reveals the molecular details of the complementarity determining regions (CDR) and substantial flexibility of CDR3 that could facilitate an induced fit interaction with gp120. Structural comparison of CDRs from other CD4 binding site antibodies suggests diverse modes of interaction. Mutational analysis identified CDR3 as a key component of gp120 interaction as determined by surface plasmon resonance. A decrease in affinity is directly coupled to the neutralization efficiency since mutations that decrease gp120 interaction increase the IC50 required for HIV-1 IIIB neutralization. Thus the structural study identifies the long CDR3 of D7 as the key determinant of interaction and HIV-1 neutralization. Furthermore, our data confirm that the structural plasticity of gp120 can accommodate multiple modes of antibody binding within the CD4 binding site.
Hinz
Andreas
A
Unit of Virus Host Cell Interactions (UVHCI), UMI 3265, Université Joseph Fourier-EMBL-CNRS, Grenoble, France.
Lutje Hulsik
David
D
Forsman
Anna
A
Koh
Willie Wee-Lee
WW
Belrhali
Hassan
H
Gorlani
Andrea
A
de Haard
Hans
H
Weiss
Robin A
RA
Verrips
Theo
T
Weissenhorn
Winfried
W
D000595:Amino Acid Sequence; D001665:Binding Sites; D015704:CD4 Antigens / Q000276:immunology; D022801:Complementarity Determining Regions / Q000737:chemistry / Q000276:immunology; D004252:DNA Mutational Analysis; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015497:HIV-1 / Q000187:drug effects; D007128:Immunoglobulin Fragments / Q000737:chemistry* / Q000276:immunology* / Q000494:pharmacology; D007143:Immunoglobulin Heavy Chains / Q000737:chemistry* / Q000276:immunology* / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D008958:Models, Molecular; D008969:Molecular Sequence Data; D050505:Mutant Proteins / Q000378:metabolism; D009500:Neutralization Tests; D011485:Protein Binding / Q000187:drug effects; D017433:Protein Structure, Secondary; D016415:Sequence Alignment; D012997:Solvents; D040681:Structural Homology, Protein; D013499:Surface Properties / Q000187:drug effects
D015704:CD4 Antigens; D022801:Complementarity Determining Regions; D015699:HIV Envelope Protein gp120; D007128:Immunoglobulin Fragments; D007143:Immunoglobulin Heavy Chains; D050505:Mutant Proteins; D012997:Solvents
Curr Opin Immunol. 1997 Aug;9(4):551-62
9287172
J Virol. 2001 Nov;75(22):10892-905
11602729
Cell. 1997 Apr 18;89(2):263-73
9108481
Nat Rev Microbiol. 2008 Feb;6(2):143-55
18197170
Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54
12393927
Nature. 2005 Feb 24;433(7028):834-41
15729334
Science. 1994 Nov 11;266(5187):1024-7
7973652
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
15299374
J Virol. 1996 Feb;70(2):1100-8
8551569
J Virol. 1994 Dec;68(12):8350-64
7525988
Biotechnol Bioeng. 2007 Feb 15;96(3):483-94
16948170
J Virol. 1993 Nov;67(11):6642-7
7692082
Nature. 1993 Jun 3;363(6428):446-8
8502296
Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7
6096719
Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
16369096
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
12019106
Nature. 2002 Dec 12;420(6916):678-82
12478295
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
15299926
AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65
11788027
J Immunol Methods. 2003 Dec;283(1-2):17-25
14659896
Nature. 1998 Jun 18;393(6686):705-11
9641684
J Virol. 2004 Dec;78(23):13232-52
15542675
J Virol. 2002 Jul;76(14):7306-21
12072529
J Mol Biol. 2006 Mar 17;357(1):82-99
16426633
J Virol. 2004 Sep;78(17):9233-42
15308718
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1166-71
20080564
J Virol. 2004 Mar;78(6):3155-61
14990736
J Virol. 1992 Sep;66(9):5635-41
1380099
Science. 2009 Oct 9;326(5950):285-9
19729618
Nature. 1998 Jun 18;393(6686):648-59
9641677
Nature. 2007 Feb 15;445(7129):732-7
17301785
Nat Struct Biol. 1996 Sep;3(9):752-7
8784347
J Virol. 2008 Dec;82(24):12069-81
18842738
J Acquir Immune Defic Syndr (1988). 1993 Jan;6(1):7-14
8417177
J Virol. 1996 Sep;70(9):6437-41
8709277
J Virol. 2007 Apr;81(8):4033-43
17287272
Curr Opin HIV AIDS. 2008 May;3(3):368-74
19372992
J Mol Biol. 1992 Oct 5;227(3):799-817
1404389
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10193-8
17540729
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
15572765
Nature. 1997 May 22;387(6631):426-30
9163431
J Infect Dis. 1997 May;175(5):1056-62
9129066
J Virol. 2005 Oct;79(20):13060-9
16189008
Science. 2001 Aug 10;293(5532):1155-9
11498595
Nat Rev Drug Discov. 2004 Mar;3(3):215-25
15031735
FEBS Lett. 2007 May 22;581(11):2150-5
17320081
PLoS One. 2010 Jan 20;5(1):e8805
20098712
J Virol. 1994 Aug;68(8):4821-8
7518527
J Virol. 2005 Aug;79(16):10108-25
16051804
J Gen Virol. 2002 Aug;83(Pt 8):1809-1829
12124446
Yeast. 1996 Apr;12(5):467-77
8740420
Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8
6083454
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
19461840
Science. 2009 Nov 20;326(5956):1123-7
19965434
J Virol. 2000 Sep;74(18):8358-67
10954535
Nat Struct Biol. 1999 May;6(5):458-63
10331874
Mol Immunol. 1994 Oct;31(15):1149-60
7935503